3 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Henning Bundgaard: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Beta 3 Agonist Treatment in Heart Failure-2 Mirabegron - Heart Failure With Reduced Ejection Fraction NYHA Class III-IV | Phase 2 / Phase 3 | Completed | Henning Bundgaard | 56 | 2017-01-23 | 2022-05-04 |
| Beta 3 Agonist Treatment in Heart Failure Mirabegron, Placebo - Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 2 | Completed | Henning Bundgaard | 70 | 2013-09-30 | 2020-10-19 |
| Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy Losartan, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Henning Bundgaard | 130 | 2011-11-01 | 2014-07-09 |
Cardiomyopathy, Hypertrophic (1) · Hypertrophy (1)
mirabegron (2) · Adrenergic beta-3 Receptor Agonists (1) · Losartan (1)
Denmark (3) · Australia (1)
PMID 25533774, PMID 26661322, PMID 27990717, PMID 38452283
2016 (1)